Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Current Assets (2020 - 2026)

RxSight filings provide 6 years of Current Assets readings, the most recent being $287.5 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 2.17% to $287.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $287.5 million, a 2.17% decrease, with the full-year FY2025 number at $287.5 million, down 2.17% from a year prior.
  • Current Assets hit $287.5 million in Q4 2025 for RxSight, up from $283.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $293.8 million in Q4 2024 to a low of $75.5 million in Q2 2021.
  • Median Current Assets over the past 5 years was $180.4 million (2023), compared with a mean of $205.3 million.
  • Biggest five-year swings in Current Assets: soared 116.31% in 2021 and later dropped 25.32% in 2022.
  • RxSight's Current Assets stood at $176.3 million in 2021, then dropped by 23.68% to $134.6 million in 2022, then increased by 25.16% to $168.4 million in 2023, then soared by 74.47% to $293.8 million in 2024, then dropped by 2.17% to $287.5 million in 2025.
  • The last three reported values for Current Assets were $287.5 million (Q4 2025), $283.9 million (Q3 2025), and $283.9 million (Q2 2025) per Business Quant data.